Pritzker M R, Lake K D, Reutzel T J, Hoffman F M, Jorgensen C R, Pederson W, Emery R W
Minneapolis Heart Institute, MN 55407.
J Heart Lung Transplant. 1992 Mar-Apr;11(2 Pt 2):415-20.
Recent advances in immunotherapy have resulted in improved survival after heart transplantation. The use of OKT3 as an induction agent has allowed the identification of a subset of patients who can be successfully withdrawn from prednisone and maintained on only cyclosporine and azathioprine. The latter regimen offers several theoretic advantages in terms of freedom from complications of long-term steroid therapy. To compare both the long-term efficacy and toxicity of steroid-free maintenance immunosuppression with triple-drug therapy, the medical records of 68 patients undergoing transplantation at the Minneapolis Heart Institute during a 3-year period (1988 through 1990) were reviewed. Thirty-six patients were treated with OKT3 induction immunotherapy, 29 were successfully tapered off prednisone by 114 +/- 44 days after transplantation, whereas 32 patients were maintained on triple-drug therapy. The incidence of treated rejection was equivalent in both groups; however, the time to first rejection was longer in patients treated with OKT3/steroid-free maintenance (205 +/- 214 vs 27 +/- 17 days) (p = 0.02). Bacterial infections during the early posttransplant period were more common in the OKT3/steroid-free maintenance group (p = 0.008); however, fungal and viral infections were equally distributed between both groups. The incidence of hypertension was slightly higher in patients maintained on prednisone (67% vs 51%; p = 0.242).(ABSTRACT TRUNCATED AT 250 WORDS)
免疫疗法的最新进展已使心脏移植后的生存率得到提高。使用OKT3作为诱导剂已使确定出一部分患者成为可能,这些患者能够成功停用泼尼松,仅用环孢素和硫唑嘌呤维持治疗。就避免长期使用类固醇疗法的并发症而言,后一种治疗方案具有几个理论上的优势。为比较无类固醇维持免疫抑制与三联药物疗法的长期疗效和毒性,回顾了明尼阿波利斯心脏研究所1988年至1990年3年期间68例接受移植患者的病历。36例患者接受OKT3诱导免疫疗法治疗,29例在移植后114±44天成功停用泼尼松,而32例患者接受三联药物疗法维持治疗。两组中经治疗的排斥反应发生率相当;然而,接受OKT3/无类固醇维持治疗的患者首次发生排斥反应的时间更长(205±214天对27±17天)(p=0.02)。移植后早期细菌感染在OKT3/无类固醇维持治疗组中更常见(p=0.008);然而,真菌和病毒感染在两组中分布相当。维持使用泼尼松的患者高血压发生率略高(67%对51%;p=0.242)。(摘要截短至250字)